BIB - ProShares Ultra Nasdaq Biotechnology

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
52.03
-3.73 (-6.69%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close55.76
Open55.03
Bid52.03 x 1000
Ask54.21 x 900
Day's Range51.98 - 55.41
52 Week Range36.05 - 70.82
Volume195,114
Avg. Volume207,278
Net Assets332.09M
NAV51.99
PE Ratio (TTM)N/A
Yield0.00%
YTD Return22.59%
Beta (3Y Monthly)2.89
Expense Ratio (net)0.95%
Inception Date2010-04-06
Trade prices are not sourced from all markets
  • MarketWatch18 days ago

    Biotech stocks turn lower after reports of FDA commissioner resigning

    Biotech stocks turned lower after news reports on Tuesday afternoon that Food and Drug Administration Commissioner Scott Gottlieb was resigning. The iShares Nasdaq Biotechnology ETF was down 0.3% after being up 0.5% just before the news. The ProShares Ultra Nasdaq Biotechnology ETF fell 0.6%, while the SPDR S&P Biotech ETF fell 0.2% . Biotech and pharmaceutical executives have praised Gottlieb for accelerating the approval of generic drugs and updating the process for FDA evaluation of novel treatments such as gene therapy.

  • Zacks5 months ago

    Stocks Still Looking for the Bottom

    Stocks Still Looking for the Bottom

  • Investor's Business Daily5 months ago

    Swing Trade In Biotech Sector Gave The Best Of Both Worlds

    Stocks in the biotech sector pose a problem for a swing trade. We take profits quicker, so we need to avoid big losses. Biotech stocks make that difficult.

  • Major Biotech ETFs Had Lackluster Performance in the Past Month
    Market Realist6 months ago

    Major Biotech ETFs Had Lackluster Performance in the Past Month

    All three major biotechnology ETFs—the SPDR S&P Biotech ETF (XBI), the iShares NASDAQ Biotechnology Index (IBB), and the ProShares Ultra Nasdaq Biotechnology ETF (BIB)—have posted returns of ~1% in last month, starting on August 10. That compares unfavorably with the performance of the SPDR S&P 500 ETF (SPY), which returned ~1.7% in the same period.

  • Biotech Funds Tacked On $76 Million This Week — Are They Recovering?
    Investor's Business Daily9 months ago

    Biotech Funds Tacked On $76 Million This Week — Are They Recovering?

    Biotech funds tacked on $76 million this week, adding to more than $500 million in net inflows over the past two weeks — a phenomenon the group hasn't seen in nine months.